<DOC>
	<DOC>NCT01332370</DOC>
	<brief_summary>This retrospective database study analyzed resource utilization and costs associated with sitagliptin (STG) in comparison with rosiglitazone (RSG) added to metformin (MET) monotherapy among adults with a diagnosis of diabetes who were continuously enrolled in a large US healthcare plan.</brief_summary>
	<brief_title>Prescription Patterns, Resource Utilization &amp; Costs - Add-on Therapy With Anti Dipeptidyl Peptidase-IVs vs Rosiglitazone</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Continuously enrolled in the health insurance plan to ensure complete claims coverage At least 1 claim with a diagnosis of diabetes (ICD9 250.xx) Aged 18 years or older at the index date At least 6 months of baseline period prior to the index date At least 1 claim for MET during the baseline period At least 180 days of continuous therapy with RSG+MET or STG+MET after the index date At least 1 claim for insulin or sulfonylurea in the baseline period At least 1 claim with a diagnosis of congestive heart failure in the baseline period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Retrospective</keyword>
	<keyword>Type 2 Diabetes</keyword>
	<keyword>Cost Analysis</keyword>
	<keyword>Rosiglitazone</keyword>
	<keyword>Sitagliptin</keyword>
</DOC>